Working as a psychiatrist and psychotherapist for more than 30 years, we came to the conclusion that when treating a patient with Clinical Hypnosis, it is important to prepare the patient with medication, which increases his suggestibility and, consequently, the effectiveness of hypnotherapy.
Depression, fear and anxiety during PANDEMIA
Fear as an adaptation reaction or a response to danger, conflict or stress.
Primary anxiety is the dominant symptom of neurotic disorders. Kinds:
- phobic - isolated anxiety associated with a specific stimulus, having a disproportionately high level and leading to avoidance of contact with threatening stimuli; occurs with phobias;
- panic - appears suddenly and lasts several tens of minutes, occurs in anxiety disorders with panic attacks (panic disorder);
- generalized - persistent, of varying intensity, manifested by excessive fears; occurs in generalized anxiety disorder;
- associated with complaints of somatic symptoms that are not confirmed by a medical examination; occurs in somatoform disorders;
- associated with a stressful situation; occurs in acute stress reactions, adaptation disorders, post-traumatic stress disorder.
Secondary anxiety - is a symptom of other diseases and disorders: mental (with depression, schizophrenia, organic disorders), somatic, associated with the use of psychoactive substances or with side effects of drugs.
Generalized Anxiety Disorder: Excessive Fear:
- concerning different life situations that are difficult to control 2) last ≥6 months;
- are accompanied by ≥3 of the following symptoms: anxiety or feeling of inner tension, rapid exhaustion, difficulty concentrating or feeling empty in the head, irritation, possibly muscle tension, insomnia.
Anxiety disorders with panic attacks: Recurrent unexpected panic attacks that accompany:
- constant fear of another panic attack;
- worry about the possible consequences of panic attacks (loss of control, threats to life);
- behavioral changes associated with seizures.
3. Anxiety disorders in the form of phobias: some specific situations cause:
- excessive or irrational anxiety in direct contact with them;
- excessive fear of contact with them;
- avoidance of such situations.
The goal of Hypnosis psychotherapy is to enhance the patient's sense of security and improve the functioning of the patient. Hypnotherapy aims at identifying the patient's most important problems and supporting them in overcoming them. Strengthening the patient's faith in his own capabilities in shears in which it is inadequately underestimated. Facilitate the response of negative emotions, giving the opportunity to "cry", "speak out", etc. Take action in the patient's immediate environment to reduce the problems that caused the symptoms.
Ketilept is an atypical antipsychotic drug that has a higher affinity for serotonin receptors (5HT2) than for dopamine D1 and D2 receptors in the brain.
Ketilept also has a higher affinity for histamine and α1 -adrenergic receptors and less in relation to α2-adrenergic receptors.
In standard tests, quetiapine exhibits antipsychotic activity.
In the course of clinical studies, no differences were found between the use of Ketilept (at a dose of 75–750 mg / day) in the occurrence of cases of extrapyramidal symptoms. Ketilept does not cause a prolonged increase in the concentration of prolactin in blood plasma.
Ketilept is used in the treatment of moderate to severe depressive episodes in the structure of bipolar disorder.
Ketilept is taken orally, regardless of food intake, 2 times a day.
Adults. The total daily dose in the first 4 days of therapy is 50 mg (on the 1st day), 100 mg (on the 2nd day), 200 mg (on the 3rd day) and 300 mg (on the 4th day).
Starting from the 4th day, the usual effective daily dose of Ketilept is 300 mg. Depending on the clinical response and tolerance in each patient, the dose can be specified in the range from 150 to 750 mg / day.
Sakellion Dimitrios Nikolaos
Doctor of Psychology, Psychiatrist,
Psychotherapist of the Highest category,
Member of the Medical College of Athens Reg. No. 065495
Member of the Pan-Hellenic Association of Psychiatrists Reg.No. A.P.1556
Member of the Pan-Greek Association of Psychotherapists
Member of the National Guild of Hypnologists NGH, USA
Scientific consultant of the clinic "EGENITIO", University of Athens, Greece.
Associate Professor of the Department of Therapeutic Directions No. 3 of the Tashkent State Dental Institute